Cytogen: Cancer patients show reduced pain with Quadramet

By E. Janene Geiss

Philadelphia, Sept. 19 - Cytogen Corp. said Tuesday that new data relating to the company's Quadramet (samarium Sm-153 lexidronam injection) product showed that patients with hormone refractory prostate cancer and painful bone metastases receiving a single dose of Quadramet improved pain intensity.

While a number of controlled and uncontrolled studies have demonstrated that Quadramet is active in the relief of pain associated with metastatic bone lesions deriving from several tumor types in 73% to 86% of patients treated, no prospective studies specifically assessed the role of this class of drugs in preventing or reducing movement-related pain, the Princeton, N.J., biopharmaceutical company said in a news release. Movement, or incident pain, is the most frequent pain in patients with cancer progression to bone.

In the study, 13 patients with hormone refractory prostate cancer and painful bone metastases received a single 1 mCi/kg dose of Quadramet. Pain intensity on movement at week four improved by at least two points in eight of the 11 patients (72.7%) who reported such pain at baseline.

The study was published in a recent issue of the peer-reviewed journal Supportive Care in Cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.